CVRx (NASDAQ:CVRX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

CVRx (NASDAQ:CVRX) announced its quarterly earnings results on Thursday. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.01), FiscalAI reports. CVRx had a negative return on equity of 120.76% and a negative net margin of 89.14%.The business had revenue of $15.71 million for the quarter, compared to analysts’ expectations of $15.55 million.

Here are the key takeaways from CVRx’s conference call:

• 2026 revenue guidance was lowered to $58 million–$60 million, with third-quarter revenue expected at $13.5 million–$14.5 million, reflecting weaker anticipated second-half performance.
• Sales execution has been hampered by high turnover and slower-than-expected ramping of new territory managers, particularly in several regions with less-tenured leadership; CVRx does not expect to add sales territories for the rest of 2026.
• A major Medicare Advantage payer’s use of new prior-authorization tactics has pushed its 30-day approval rate below 30%, making physicians more hesitant to recommend Barostim for patients covered by that plan.
• Reimbursement trends outside that payer are improving, including a 60% overall Medicare Advantage 30-day approval rate, approval rates above 90% with Humana, approximately 96% payment across traditional Medicare contractors, and higher inpatient payment rates.
• CVRx reported second-quarter revenue of $15.7 million, up 16% year over year, and said the BENEFIT-HF trial is ahead of expectations for site activation and enrollment; however, the company also disclosed a Department of Justice civil investigative demand related to certain sales and marketing practices.

CVRx Stock Performance

CVRx stock traded down $3.55 during mid-day trading on Friday, reaching $2.39. The company’s stock had a trading volume of 14,659,737 shares, compared to its average volume of 417,343. The company has a current ratio of 10.20, a quick ratio of 8.89 and a debt-to-equity ratio of 2.01. CVRx has a twelve month low of $2.30 and a twelve month high of $11.30. The business has a 50 day moving average price of $5.26 and a 200-day moving average price of $6.52. The firm has a market cap of $63.43 million, a price-to-earnings ratio of -1.18 and a beta of 0.81.

Analyst Ratings Changes

A number of brokerages have commented on CVRX. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a research note on Monday. Wall Street Zen upgraded CVRx from a “sell” rating to a “hold” rating in a report on Saturday, June 27th. Lake Street Capital lowered CVRx from a “buy” rating to a “hold” rating and set a $3.50 target price on the stock. in a research report on Friday. Piper Sandler cut CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Friday. Finally, Craig Hallum downgraded shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 price objective on the stock. in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $6.90.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of CVRx during the 4th quarter valued at about $79,000. Corient Private Wealth LLC bought a new position in CVRx in the fourth quarter worth about $81,000. XTX Topco Ltd acquired a new position in CVRx in the fourth quarter valued at approximately $90,000. Alliancebernstein L.P. boosted its stake in CVRx by 10.7% in the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after acquiring an additional 1,700 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in shares of CVRx by 61.3% during the fourth quarter. Wells Fargo & Company MN now owns 20,266 shares of the company’s stock valued at $144,000 after purchasing an additional 7,705 shares during the last quarter. 75.27% of the stock is currently owned by institutional investors.

More CVRx News

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, slightly above the $15.55 million analyst consensus. Its per-share loss of $0.53 was also an improvement from a $0.57 loss a year earlier, although it narrowly missed the $0.52 consensus loss. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Despite downgrading the shares to “hold,” Lake Street Capital and Craig Hallum set price targets of $3.50 and $4.00, respectively—above the current trading level—suggesting potential recovery if execution improves. The Fly analyst ratings
• Neutral Sentiment: Johnson Fistel said it is investigating whether CVRx or certain executives violated securities laws in connection with the guidance reduction and sales-execution disclosures. The announcement is an investigation notice, not a finding of wrongdoing, but it adds headline and legal risk. Johnson Fistel investigation notice
• Negative Sentiment: CVRx cut third-quarter revenue guidance to $13.5 million-$14.5 million, well below the $16.9 million consensus, and reduced full-year 2026 revenue guidance to $58 million-$60 million from an implied level near the $65.4 million consensus. Management cited slower sales productivity and Medicare Advantage-related headwinds. CVRx forecasts 2026 revenue
• Negative Sentiment: The quarterly loss slightly exceeded expectations, while CVRx continues to report deeply negative profitability, including a negative net margin and negative return on equity. Analysts responded by downgrading the stock from “buy” to “hold,” reinforcing concerns about near-term growth and execution. CVRx Q2 2026 earnings call transcript

About CVRx

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.